Status unknownNCT05158803Updated Dec 15, 2021

Lung Ultrasound in Comparison With C.T in Covid-19

An observational study in COVID-19, sponsored by Sohag University. Status unknown. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2021-12-15.

Sponsored by Sohag University · Observational

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Study type: Observational
Model: Case-only
Time perspective: Prospective
Enrollment: 200
Ages: 18 Years to 95 Years
Sex: All

Study summary

investigate the diagnostic ability of thoracic ultrasound in suspicious COVID-19 infection and/or COVID-19 pneumonia. Also, to compare its findings to CT and follow up these findings.

Read the detailed description

ultrasound and C.T will be assessed in acute presentation of Covid 19 patients and then those patients will be reassessed again after 1 month by lung ultrasound and C.T and if ultrasound will show the same efficacy of diagnosis or not

Conditions studied

COVID-19

Browse trials for

COVID-19 7,775

In context

COVID-19

7,775 studies on the registry are indexed under COVID-19; 482 are open to participants now.

This study's planned enrollment of 200 is below the median of 260 across 3,188 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Sohag University is the lead sponsor of 1,220 studies on the registry; 629 are open to participants now.

Browse Sohag University studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 95 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

covid 19 patients in acute phase and follow up after 1 and 2 months

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

all cases of covid 19 patients

Exclusion criteria

Exclusion Criteria:

all other causes of consolidation ,ground glass fibrosis or collapse findings of C.T and ultrasound

Study design

Observational model: Case-only
Time perspective: Prospective
Enrollment: 200 participants (estimated)
Patient registry: No

Groups and cohorts

covid 19 in acute phase
Radiation: ultrasound and C.T
covid 19 follow up
Radiation: ultrasound and C.T

Interventions

Radiationultrasound and C.T
lung ultrasound in comparison to C.T

What researchers measure

Primary outcomes

diagnostic ability of thoracic ultrasound for diagnosis and follow up of covid19 patients
compare lung ultrasound with C.T finding of covid 19 patients
Time frame: after 1 month of acute presentation

Study locations

No study locations are listed for this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2022; primary completion for Jan 2024, 24 months later.

Of 1,625 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 29. This study's planned 24 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered: Dec 12, 2021
First posted: Dec 15, 2021
StartEst.: Jan 1, 2022
Primary completionEst.: Jan 2024
CompletionEst.: Dec 30, 2024
Last update: Dec 15, 2021

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Dec 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05158803
Lead sponsor: Sohag University
Responsible party: Esraa Mohamed Amin (Sohag university, Sohag University) — Principal investigator
First posted: Dec 15, 2021
Start date: Jan 1, 2022 (estimated)
Primary completion: Jan 2024 (estimated)
Completion: Dec 30, 2024 (estimated)
Last update: Dec 15, 2021

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

COVID-19 →

Other studies from this sponsor

Sohag University →

Start the discussion